- Home
- NYC vs SABS Comparison
NYC vs SABS Comparison
Compare NYC & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- SABS
- Stock Information
- Founded
- NYC 2013
- SABS 2014
- Country
- NYC United States
- SABS United States
- Employees
- NYC N/A
- SABS N/A
- Industry
- NYC Real Estate
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- SABS Health Care
- Exchange
- NYC Nasdaq
- SABS Nasdaq
- Market Cap
- NYC 23.8M
- SABS 23.9M
- IPO Year
- NYC N/A
- SABS N/A
- Fundamental
- Price
- NYC $8.51
- SABS $3.34
- Analyst Decision
- NYC
- SABS Strong Buy
- Analyst Count
- NYC 0
- SABS 5
- Target Price
- NYC N/A
- SABS $12.40
- AVG Volume (30 Days)
- NYC 3.3K
- SABS 83.3K
- Earning Date
- NYC 11-12-2024
- SABS 11-06-2024
- Dividend Yield
- NYC N/A
- SABS N/A
- EPS Growth
- NYC N/A
- SABS N/A
- EPS
- NYC N/A
- SABS N/A
- Revenue
- NYC $62,060,000.00
- SABS $1,512,723.00
- Revenue This Year
- NYC N/A
- SABS N/A
- Revenue Next Year
- NYC $3.18
- SABS N/A
- P/E Ratio
- NYC N/A
- SABS N/A
- Revenue Growth
- NYC N/A
- SABS N/A
- 52 Week Low
- NYC $5.46
- SABS $2.16
- 52 Week High
- NYC $10.91
- SABS $7.70
- Technical
- Relative Strength Index (RSI)
- NYC 47.19
- SABS 48.06
- Support Level
- NYC $7.96
- SABS $2.75
- Resistance Level
- NYC $9.15
- SABS $4.30
- Average True Range (ATR)
- NYC 0.50
- SABS 0.51
- MACD
- NYC 0.05
- SABS 0.03
- Stochastic Oscillator
- NYC 49.21
- SABS 26.11
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.